Keith Katkin

Keith is a seasoned biopharma executive, serving as Chairman, CEO, and Board Member for multiple companies. He specializes in late-stage drug development, FDA approvals, and strategic exits, notably leading Avanir Pharmaceuticals to a $3. 5 billion acquisition. Keith holds an MBA from UCLA Anderson and a BS from Indiana University, and is a licensed Certified Public Accountant.

While his professional life is demanding, Keith maintains a connection to his academic roots, showing interest in his alma maters, Indiana University and the UCLA Anderson School of Management. This suggests an appreciation for the foundational role these institutions played in his successful career in the biopharmaceutical industry.

He co-founded Ambros Therapeutics to address a critical unmet need, stating, "There are no medicines approved for CRPS-1 patients in the U. S. "